Table 2.
Main clinical outcomes were resulting from treatments.
| SC |
SC+P |
|||
|---|---|---|---|---|
| AOx | Placebo | AOx | Placebo | |
| T0 | ||||
| AK countc | 7 (6–10) | 7 (7–9) | 7 (6–9) | 6 (6–8) |
| FPSc | 105 (94–114) | 105 (94–114) | 113 (73–117) | 108 (78–117) |
| AKSSc | 81 (46–95) | 69 (46–111) | 70 (53–92) | 70 (52–89) |
| T60 | ||||
| Total clearanced | 2 (10) | 1 (5) | 1 (5) | – (–) |
| FPSc | 79 (66–93)a | 78 (68–93)a | 81 (68–94)a | 85 (74–95)a |
| AKSSc | 34 (13–51)a | 38 (18–62)a | 20 (11–30)a | 32 (22–43)a |
| AK countc | 4 (3–6)a, b | 5 (4–7)a | 4 (2–5)a, b | 5 (3–7) |
| Partial clearanced | 8 (40)b | 5 (25) | 10 (50)b | 4 (20) |
SC, Regular sunscreen group; SC+P, Sunscreen group with photolyase; AOx, Group with topical antioxidant; FPS, forearm photoageing scale; AKSS, forearm AK severity score.
a
p < 0.05 (T0 vs. T60).
b
p < 0.05 (AOx vs. Placebo).
c
Median (p25-p75).
d
n (%).